Premium
Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single‐dose cyclophosphamide combined with rhGM‐CSF or rhG‐CSF
Author(s) -
DEMUYNCK HILDE,
DELFORGE MICHEL,
VERHOEF GREGOR,
ZACHEE PIERRE,
VANDENBERGHE PETER,
BOOGAERTS MARC
Publication year - 1995
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1995.tb05163.x
Subject(s) - multiple myeloma , cyclophosphamide , medicine , peripheral blood , progenitor cell , lenalidomide , oncology , chemotherapy , stem cell , biology , genetics
Summary. Patients suffering from high‐risk multiple myeloma (MM) were randomized to receive single high‐dose cyclophosphamide followed by either rhGM‐CSF or rhG‐CSF in order to harvest circulating peripheral blood progenitor cells. The safety of the procedure, the mobilization kinetics, the relative efficacy of rhGM‐CSF and rhG‐CSF to mobilize progenitor cells and their relative toxicity were studied. Special attention was paid to the antigenic profile of CD34 + progenitor cells. Group I patients (n=ll) were treated with cyclophosphamide 4 g/m 2 i.v. followed by rhGM‐CSF at 10 /ig/kg/d by subcutaneous administration. Group II (n=ll) patients received rhG‐CSF s.c. at 10/zg/kg/d after the same dose cyclophosphamide. Both mobilization regimens appeared to be equally effective. No significant differences in absolute numbers of circulating progenitors, determined by CD34 expression or in yields of MNC, CFU‐GM, BFU‐E and CD34 subsets were observed. rhGM‐CSF administration resulted however in delayed haemopoietic recovery and an increased complication rate. We conclude that rhG‐CSF may be preferred because of its markedly lower toxicity and lower in‐hospital costs.